专利号:WO-2024168411-A1 优先权日:2023-02-15 标题 :Food additive and/or food supplement, production method, formulation of functional food and/or food supplement, use 发明人:HEIMANN ANDREA STERMAN; KRONGRAD ARNON 权利人:PROTEIMAX BIO TECH ISRAEL LTD; HEIMANN ANDREA STERMAN 摘要:The present invention pertains to the field of biotechnology, nutrition and protein synthesis. More specifically, the invention discloses a food additive, the use thereof, a process for the solid-phase synthesis of a peptide providing a reduction in the generation of toxic by-products, a food and/or food supplement formulation comprising said additive and/or supplement. In one embodiment, said peptide is of SEQ ID NO: 1, Asp-Ile-Ile-Ala-Asp-Asp-Glu-Pro-Leu-Thr, or DIIADDEPLT, also known as Pep19 or WATACAP. The food additive and/or supplement of the invention comprises said peptide and provides essential amino acids that promote metabolic improvements in vertebrates, including humans and dogs.
1: Hennessey JV. The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2017 Jan;55(1):6-18. doi: 10.1007/s12020-016-1199-8. Epub 2016 Dec 16. 39(2):378-403. doi: 10.1016/j.clinthera.2017.01.005. Epub 2017 Jan 30. 380(14):1316-1325. doi: 10.1056/NEJMoa1812537. Epub 2019 Mar 23. 18(4):451-6. 36(Suppl 2):30-46. doi: 10.1007/s12325-019-01078-2. Epub 2019 Sep 4. 6: Azran C, Porat D, Fine-Shamir N, Hanhan N, Dahan A. Oral levothyroxine therapy postbariatric surgery: Biopharmaceutical aspects and clinical effects. Surg Obes Relat Dis. 2019 Feb;15(2):333-341. doi: 10.1016/j.soard.2019.01.001. Epub 2019 Jan 10. 28(4):454-457. doi: 10.1089/thy.2017.0428. Epub 2018 Mar 28. 8: Geer M, Potter DM, Ulrich H. Alternative schedules of levothyroxine administration. Am J Health Syst Pharm. 2015 Mar 1;72(5):373-7. doi: 10.2146/ajhp140250. 36(Suppl 2):59-71. doi: 10.1007/s12325-019-01079-1. Epub 2019 Sep 4.
合成参考文献
参考文献:10.1208/s12249-011-9660-8 摘要:Kocic I, Homsek I, Dacevic M, Parojcic J, Miljkovic B. An investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability. AAPS PharmSciTech. 2011 Sep;12(3):938–48.